Bajaj Healthcare

Why is Bajaj Healthcare Ltd falling/rising?

As of 24-Aug, Bajaj Healthcare Ltd's stock price is currently at 321.40, reflecting a downward trend with a total decline of -1.41% over the last two days and a year-to-date drop of -22.60%. The stock is trading below all major moving averages, indicating bearish sentiment and reduced investor interest.

As of 24-Aug, Bajaj Healthcare Ltd's stock price is falling, currently at 321.40, reflecting a decrease of 0.5 (-0.16%). The stock has been on a downward trend, having lost value for the last two consecutive days, resulting in a total decline of -1.41% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Investor participation has also decreased, with the delivery volume on 21 August falling by -5.89% compared to the 5-day average. This decline in trading activity suggests reduced interest among investors. Furthermore, the stock has underperformed significantly over longer periods, with a year-to-date decline of -22.60% compared to the Sensex's -9.21%, and a one-year drop of -27.64% against the Sensex's -4.84%. These factors collectively contribute to the ongoing decline in Bajaj Healthcare Ltd's stock price.

Which are the latest news on Bajaj Healthcare?

Who are in the management team of Bajaj Healthcare?

The management team of Bajaj Healthcare includes Sanjankumar R Bajaj (Chairman & Managing Director), Anil C Jain (Joint Managing Director), and several other directors, including independent and whole-time directors, overseeing the company's operations and strategy.

The management team of Bajaj Healthcare includes the following key members:<BR><BR>1. **Sanjankumar R Bajaj** - Chairman & Managing Director<BR>2. **Anil C Jain** - Joint Managing Director<BR>3. **Namrata S Bajaj** - Whole-time Director<BR>4. **Dhananjay S Halte** - Whole-time Director<BR>5. **Rupesh H Nikam** - Whole Time Director & CFO<BR>6. **Ram B Banarase** - Independent Director<BR>7. **Hemant R Karnik** - Independent Director<BR>8. **Aakashkumar Kesari** - Company Secretary<BR>9. **Avinash Dalal** - Independent Director<BR>10. **Loukik D Tipnis** - Independent Director<BR>11. **Luke Benedict Fernandez** - Independent Director<BR>12. **Kejal Shah** - Independent Director<BR>13. **Pakshal Jain** - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Bajaj Healthcare do?

Bajaj Healthcare Ltd is a micro-cap bulk drug manufacturer in the Pharmaceuticals & Biotechnology industry, established in 1993 and publicly listed since 2016. As of June 2026, it reported net sales of ₹166 Cr and a net profit of ₹14 Cr, with a market cap of ₹1,130 Cr.

Overview: <BR>Bajaj Healthcare Ltd is a bulk drug manufacturer operating in the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Bajaj Healthcare Ltd was established in 1993 and became a public company in 2005. It listed its shares on the Indian stock exchanges in 2016. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 166 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 14 Cr (Quarterly Results - Jun 2026) <BR>Market cap: INR 1,130 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.29% <BR>Debt-Equity: 0.46 <BR>Return on Equity: 11.49% <BR>Price to Book: 2.27<BR><BR>Contact Details: <BR>Address: 602-606 Bhoomi Velocity Infote, Road No 23 Wagle Indl Estate Thane Maharashtra : 400604 <BR>Tel: 91-22-66177400/401 <BR>Email: investors@bajajhealth.com <BR>Website: http://www.bajajhealth.com

Who are the peers of the Bajaj Healthcare?

Bajaj Healthcare's peers include Jagsonpal Pharma, Amrutanjan Health, Fermenta Biotec, and others. It has average management risk and below average growth, with a 1-year return of -27.95%, better than Amrutanjan Health but worse than Fermenta Biotec's 27.76%.

Peers: The peers of Bajaj Healthcare are Jagsonpal Pharma, Amrutanjan Healt, Fermenta Biotec., Lincoln Pharma., Sigachi Indust., Themis Medicare, Bharat Parenter., Wanbury, Accent Microcell, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, Lincoln Pharma., Sigachi Indust., and Accent Microcell, while Average management risk is found at Jagsonpal Pharma, Fermenta Biotec., Bajaj Healthcare, Themis Medicare, Wanbury, and Remus Pharma. Below Average management risk is noted at Bharat Parenter. Growth is rated as Good for Accent Microcell, while Average growth is seen at Wanbury, and Below Average growth is found at Jagsonpal Pharma, Amrutanjan Healt, Fermenta Biotec., Lincoln Pharma., Bajaj Healthcare, Sigachi Indust., Themis Medicare, and Bharat Parenter. Capital Structure is Excellent for Amrutanjan Healt, Lincoln Pharma., Sigachi Indust., and Accent Microcell, while Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Bharat Parenter., and Wanbury have a Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fermenta Biotec. at 27.76%, while the peer with the lowest is Amrutanjan Healt at -27.87%. Bajaj Healthcare's 1-year return is -27.95%, which is lower than Fermenta Biotec. but higher than Amrutanjan Healt. Additionally, the six-month return is negative for Bajaj Healthcare, Amrutanjan Healt, Lincoln Pharma., Wanbury, and Remus Pharma.

How big is Bajaj Healthcare?

As of 14th August, Bajaj Healthcare Ltd has a market capitalization of 1,117.00 Cr, with net sales of 627.82 Cr and a net profit of 17.63 Cr over the latest four quarters.

As of 14th August, Bajaj Healthcare Ltd has a market capitalization of 1,117.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bajaj Healthcare reported net sales of 627.82 Cr and a net profit of 17.63 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 466.16 Cr and total assets of 814.15 Cr.

Are Bajaj Healthcare Ltd latest results good or bad?

Bajaj Healthcare Ltd's latest results show a significant recovery in net profit and sales growth, indicating improved operational performance. However, concerns about long-term sales decline and profitability sustainability suggest caution in evaluating the company's overall health.

Bajaj Healthcare Ltd's latest results show a mixed picture. On one hand, the company reported a significant recovery in net profit, achieving ₹13.89 crores, which is a remarkable 171.54% increase quarter-on-quarter and a 14.13% increase year-on-year. This recovery follows a challenging previous quarter where the company posted a loss.<BR><BR>Net sales also grew, reaching ₹165.63 crores, marking an 8.21% increase from the previous quarter and an 11.28% increase year-on-year, which is the highest quarterly revenue in recent history. Additionally, operating margins improved to 17.36%, up from 14.82% in the prior quarter, indicating better cost management.<BR><BR>However, despite these positive developments, there are underlying concerns. The company has faced a long-term decline in sales and profitability, with a five-year annual sales decline of 1.44% and EBIT contraction of 8.46%. The current profitability, while improved, still raises questions about sustainability, especially given the volatility in quarterly earnings.<BR><BR>In summary, while the latest results indicate a recovery and improved operational metrics, the persistent structural challenges and historical performance issues suggest that caution is warranted when evaluating the overall health of Bajaj Healthcare Ltd.

Should I buy, sell or hold Bajaj Healthcare Ltd?

Is Bajaj Healthcare technically bullish or bearish?

As of December 1, 2025, Bajaj Healthcare's technical trend has shifted to a moderate bearish stance, indicated by bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Bajaj Healthcare is bearish with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. The KST shows a mildly bullish signal on the weekly but remains mildly bearish on the monthly, indicating some divergence. Overall, the lack of strong signals from the RSI and Dow Theory further supports the bearish outlook.

How has been the historical performance of Bajaj Healthcare?

Bajaj Healthcare's historical performance has shown significant fluctuations, with net sales peaking at 645.80 Cr in Mar'23 but declining to 542.60 Cr by Mar'25, alongside decreases in profit metrics and cash flow, despite an increase in total assets. Overall, the company has faced both growth and challenges in its financial performance.

Answer:<BR>The historical performance of Bajaj Healthcare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Bajaj Healthcare's net sales have experienced variability, peaking at 645.80 Cr in Mar'23 before declining to 542.60 Cr in Mar'25. The total operating income followed a similar trend, with a high of 679.89 Cr in Mar'22 and a decrease to 542.60 Cr in Mar'25. Raw material costs rose from 291.33 Cr in Mar'19 to 307.11 Cr in Mar'25, while total expenditure, excluding depreciation, increased from 327.55 Cr in Mar'19 to 460.17 Cr in Mar'25. Operating profit (PBDIT) fluctuated, reaching a high of 143.23 Cr in Mar'21 but dropping to 101.83 Cr in Mar'25. Profit before tax saw a significant decline from 118.82 Cr in Mar'21 to 46.01 Cr in Mar'25, with profit after tax also decreasing from 83.11 Cr in Mar'21 to 42.93 Cr in Mar'25. The company's total assets increased from 342.95 Cr in Mar'20 to 814.15 Cr in Mar'25, while total liabilities rose from 182.57 Cr in Mar'21 to 272.27 Cr in Mar'25. Cash flow from operating activities showed a decline from 43.00 Cr in Mar'21 to 21.00 Cr in Mar'25, with net cash inflow remaining stable at 0.00 Cr in Mar'25. Overall, Bajaj Healthcare's financial performance reflects a mix of growth and challenges over the years.

Is Bajaj Healthcare overvalued or undervalued?

As of November 7, 2025, Bajaj Healthcare is considered overvalued with a PE ratio of 27.28, significantly higher than its peers like Cipla and Dr. Reddy's Labs, and has underperformed the Sensex with a year-to-date return of -24.7%.

As of 7 November 2025, Bajaj Healthcare's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 27.28, an EV to EBITDA of 18.91, and a PEG ratio of 0.83, which suggests that while the company is growing, its valuation may not be justified by its earnings growth prospects.<BR><BR>In comparison to its peers, Bajaj Healthcare's PE ratio is notably higher than Cipla's 22.33, which is rated attractive, and Dr. Reddy's Labs at 17.43, also attractive. This indicates that Bajaj Healthcare is trading at a premium relative to these competitors despite not offering a significantly better growth outlook. Additionally, the stock has underperformed against the Sensex in the year-to-date period, with a return of -24.7% compared to the Sensex's 6.50%, further reinforcing the notion that the stock may be overvalued in the current market environment.

Who are the top shareholders of the Bajaj Healthcare?

The top shareholders of Bajaj Healthcare include Sajankumar Rameshwarlal Bajaj with 37.59%, individual investors with 26.72%, and institutional investors, including mutual funds at 1.64% and foreign institutional investors at 1.05%. The largest public shareholder is Vanaja Sundar Iyer, holding 2.22% of the shares.

The top shareholders of Bajaj Healthcare include the promoters, with Sajankumar Rameshwarlal Bajaj holding the highest stake at 37.59%. Additionally, individual investors collectively own 26.72% of the shares. The company also has some institutional investment, with mutual funds holding 1.64% through one scheme and foreign institutional investors (FIIs) holding 1.05% across ten different entities. The highest public shareholder is Vanaja Sundar Iyer, who holds 2.22% of the shares.

When is the next results date for Bajaj Healthcare?

No Upcoming Board Meetings

What is the bonus history of the Bajaj Healthcare?

Bajaj Healthcare announced a 1:1 bonus issue on April 9, 2019, with a record date of April 10, 2019, granting shareholders one additional share for each share held.

Bajaj Healthcare has a bonus history that includes a 1:1 bonus issue announced on April 9, 2019. The record date for this bonus was April 10, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Bajaj Healthcare declared dividend?

Yes, Bajaj Healthcare Ltd has declared a 20% dividend, amounting to ₹1 per share, with an ex-date of September 23, 2024. The company has shown strong total returns over various periods, including a 310.14% return over the last 5 years.

Bajaj Healthcare Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Bajaj Healthcare experienced a price return of 21.85%, with no dividend return, resulting in a total return of 21.85%.<BR><BR>Over the past year, the company saw a price return of 81.69% and a dividend return of 0.32%, leading to a total return of 82.01%.<BR><BR>In a 2-year period, the price return was 76.99%, with a dividend return of 0.64%, culminating in a total return of 77.63%.<BR><BR>For the 3-year period, the price return stood at 67.82%, while the dividend return was 1.26%, resulting in a total return of 69.08%.<BR><BR>In the 4-year timeframe, the price return was 36.62%, with a dividend return of 1.04%, leading to a total return of 37.66%.<BR><BR>Over the last 5 years, Bajaj Healthcare achieved a remarkable price return of 307.08% and a dividend return of 3.06%, resulting in a total return of 310.14%.<BR><BR>Overall, Bajaj Healthcare's dividend declaration reflects a commitment to returning value to shareholders, and the substantial total returns across various periods indicate strong performance and growth potential for the company.